This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rudbach, J.A. Articles by Sowell, C.G. Search for Related Content PubMed Articles by Rudbach, J.A. Articles by Sowell, C.G. Social Bookmarking                   What's this?

Calculating therapeutic indices and therapeutic advantages for endotoxins and monophosphoryl lipid A: an evaluation of data from the scientific literature

Ribi ImmunoChem Research, Inc., Hamilton, Montana, USA

D.S. Keegan

Ribi ImmunoChem Research, Inc., Hamilton, Montana, USA

C.G. Sowell

Ribi ImmunoChem Research, Inc., Hamilton, Montana, USA

This review article addresses the question of whether or not monophosphoryl lipid A offers a therapeutic advantage over smaller doses of endotoxin. Biological data were collected from a literature review and these were used to calculate therapeutic indices for monophosphoryl lipid A and endotoxin. Subsequent calculations yielded results which showed that, in humans and in other animals, monophosphoryl lipid A did have a therapeutic advantage over smaller doses of endotoxin.

Journal of Endotoxin Research, Vol. 2, No. 4, 301-310 (1995)
DOI: 10.1177/096805199500200410


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. E. Somerville Jr., L. Cassiano, and R. P. Darveau Escherichia coli msbB Gene as a Virulence Factor and a Therapeutic Target Infect. Immun., December 1, 1999; 67(12): 6583 - 6590. [Abstract] [Full Text] [PDF]